JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 61)

[spaceistheplace]

Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
Head-to-Head Study Demonstrated Similar & Low Rates of Major Bleeding for Both Drugs

ATLANTA, Dec 08, 2007 (BUSINESS WIRE) -- Results from a Phase III trial in patients undergoing total hip replacement surgery presented today showed that administration of the oral, once-daily, investigational anticoagulant, rivaroxaban, was statistically superior to once-daily subcutaneous administration of enoxaparin, the current standard of care in preventing venous thromboembolism (VTE) in patients following hip replacement surgery. Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

Data from the RECORD1 study show that rivaroxaban demonstrated a 70% relative risk reduction (RRR) (p less than 0.001) in total VTE when compared with enoxaparin, and an 88% RRR (p less than 0.001) in major VTE. Rivaroxaban demonstrated a similar rate of both major bleeding (0.3% and 0.1%, respectively, p=0.178) and non-major bleeding (5.8% and 5.8% p=1.000) compared to enoxaparin.

These data were released today at a press conference during the 49th Annual Meeting of the American Society of Hematology (ASH) by Dr. Bengt Eriksson, Orthopedic Surgeon at the Sahlgrenska University Hospital/Ostra, Gothenburg, Sweden, and Principal Investigator of the RECORD1 clinical trial. In addition, Dr. Eriksson will present the RECORD1 results at the major plenary session on Sunday, December 9th.

Rivaroxaban is a novel, oral, once-daily direct Factor Xa inhibitor in advanced clinical development for a range of patients who could benefit from the prevention and/or treatment of blood clots. Rivaroxaban works at a pivotal stage in the coagulation process to directly inhibit the enzyme Factor Xa.

The RECORD1 (REgulation of Coagulation in major Orthopedic surgery reducing the Risk of DVT and PE) clinical trial evaluated the safety and efficacy of rivaroxaban with enoxaparin in patients undergoing total hip replacement surgery. The duration of thromboprophylaxis in both treatment groups was five weeks. The primary endpoint was total VTE (composite of deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality) and the main secondary endpoint was major VTE (composite of proximal deep vein thrombosis, non-fatal pulmonary embolism and VTE-related death).

Further Phase III data evaluating rivaroxaban in major orthopedic surgery - including results from the RECORD2 and RECORD3 clinical trials - will be presented during oral sessions on Monday, December 10th at the ASH meeting in Atlanta. The corresponding abstracts (#307 and #308) may be viewed online at the ASH website at www.hematology.org/meetings/abstracts.cfm.

About Rivaroxaban

To date, rivaroxaban is the most studied oral, direct Factor Xa inhibitor in clinical development. More than 20,000 patients have been evaluated in the completed Phase II programs and enrolled thus far in the Phase III programs. Almost 50,000 patients are expected to be evaluated in the total clinical development program.

Bayer HealthCare submitted a regulatory filing to the European Agency for the Evaluation of Medicinal Products (EMEA) at the end of October 2007 for approval to market rivaroxaban in the EU for the prevention of VTE in patients undergoing major orthopedic surgery of the lower limbs. Upon regulatory approval, rivaroxaban will be commercialized in Europe by Bayer Schering Pharma. A filing for rivaroxaban for a similar indication in the United States is planned in 2008, where upon approval, it will be commercialized by Scios Inc. and Ortho-McNeil, Inc., both of which are wholly-owned subsidiaries of Johnson & Johnson.

Johnson & Johnson Pharmaceutical Research and Development

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from J&JPRD's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. J&JPRD does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

SOURCE: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

[spaceistheplace]

Schöner Artikel der Fools zur Unterbewertung von JNJ:

Mano a Mano Over Johnson & Johnson
By Anders Bylund November 29, 2007

3 Recommendations

One year ago, two Fools traded virtual punches over Johnson & Johnson (NYSE: JNJ). It's time to apply the benefit of hindsight to find out who presented the sounder argument.

Bulls on parade
Steven Mallas traded his jester's cap for a set of bullish horns, in shocked disbelief that anyone would actually take the opposite view.

This is, after all, the very blueprint of a blue chip, a company so large and so well known that introductions are pointless. Working through more than 200 subsidiary operations, J&J is a giant in health care and consumer goods fully on par with Merck (NYSE: MRK) or Pfizer (NYSE: PFE) on the one hand, and Procter & Gamble (NYSE: PG), Kimberly-Clark (NYSE: KMB), or Colgate-Palmolive (NYSE: CL) on the other.

There was a 44-year history of annual dividend growth (45 years now), $50 billion in annual sales, and a most impressive long-term stock chart. "The pharmaceutical industry will be important to baby boomers, as well as to everyone else for an eternal time period," Steven said. "J&J will take advantage of that need. It will reap huge amounts of free cash flow from its drug development and its consumer-products division."

Whip it!
Brian Lawler wielded the bear claws, and the battle was on. Brian agreed that J&J was a great company with a blue-chip pedigree, but he thought the gravy train had reached the end of the growth line.

"Sure, flat operating margins and slow operating-income increases can be forgivable if revenues continue to grow strongly, but sales growth has been anemic in recent years for J&J," he said. Declining sales of drug-coated stents and expiring drug patents spelled more trouble for the company, and with such a massive market cap, it just wasn't realistic to believe in much more growth. And new drug development is such a risky and costly business that you just never know what J&J's future will look like.

Our readers thought Steven had made his point and gave him 71% of 263 votes. Brian had to settle for 19% of the ballots, and 10% remained undecided. That's a landslide bullish victory on the popular vote.

Je t'aime ... moi non plus
Mr. Market tells a different story. The share price went south over the summer, losing nearly 10% of the cap value it sported late last November. A recent rally has brought J&J back into the black, but the stock still hasn't even matched the performance of S&P 500 Spiders (AMEX: SPY) over the last 12 months. We're tied at one-all.

The CAPS community still loves J&J, though. About 95% of more than 5,400 players with an opinion on the stock give it a thumbs-up, and its rating oscillates between four and five stars. A recent re-Duel over the company also showed that a Foolish bull argument still makes sense -- the landslide victory margin turned into a veritable avalanche this time. All in all, this referee has to award the victory to Steven and the bulls. Congrats!

Don't get me wrong
Aside from technicalities like community votes and stock performance, I have to tell you that Johnson & Johnson is a peerless juggernaut of a company that looks more undervalued than stalled today.

The stock's enterprise value trades today at just 21 times trailing-12-months free cash flow. The only time in the past 12 years the stock was available on the cheap like this was when Merck's Vioxx woes dragged the whole sector down in 2004. Otherwise, price-to-cash-flow ratios like to hover around the mid-30s or better.

This massive discount only makes sense if J&J somehow broke in the past couple of years. I don't think it did. In fact, the company looks healthier than ever as baby boomers get set to retire soon. J&J has fortified its consumer products department with a few choice acquisitions, too. I have to agree with Steven: What's not to love?

You might agree -- maybe you don't. Either way, I'd encourage you to mosey on over to Motley Fool CAPS and tell everybody why you feel that way. Click here, rate the stock to taste, and pen a glowing sonnet or scathing diatribe on the company, this article, or the baggage retrieval system they've got at Heathrow -- whatever concerns you the most. It's fun, it's free, and you'll make us all a bit smarter.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.623.600 von benny_m am 30.11.07 09:24:52

dazu wird derzeit vermutlich in den USA auch einiges in nicht-zyklische Werte umgeschichtet.

Ja, wird auch höchste zeit, denn in Phasen abschwächenden Wirtschaftswachstums sind eben Zykliker vorerst mal out.

Das sagen wir ja im Gewinner-Thread schon lange, dass die großen US-Multis aktuell zu günstigen Preisen zu haben sind.

Gruss space

[benny_m]

J&J hatte auch keine großartigen Kursgewinne abzugeben. Außerdem sind sie ja bei 60 USD durch das Rückkaufprogramm begrenzt.

Außerdem hat Buffets Firma ja ziemlich nachgelegt... was ja auch immer zu steigendem Interesse privater Leute führt... dazu wird derzeit vermutlich in den USA auch einiges in nicht-zyklische Werte umgeschichtet.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.623.443 von benny_m am 30.11.07 09:11:48

Ich würde eher sagen man befindet sich in USD seit 3 Jahren in einer Seitwärtsbewegung.

Und in der gleichen zeit die Gewinne um rd. 40% gesteigert. herrchen/Hund-Prinzip trifft hier auch zu, wobei der Hund klar hinter dem Herrchen her läuft...die Bewertung ist von KGV über 25 auf 18 zurückgekommen.


Desweiteren hat J&J ja auch einige Probleme und wird deshalb derzeit nicht höher bewertet.

Die werden die aber früher oder später lösen, da bin ich mir sicher. Management ist 1A!

Die Qualität des Unternehmens sieht man schon allein in den letzten Wochen, als JNJ der allg. fallenden Börsen steigende Kurse entgegengesetzt hat. Klar kann man da nicht das schnelle geld machen, will ich auch gar nicht. 10-12% pro Jahr plus 2,5% Divi, die jährlich um rd. 15% angehoben wird (zumindest wars in den letzten 10 Jahren so), reicht mir vollkommen. Absolut sicherer tanker, mit dem man alle Krisen durchschiffen kann. Grundsätzlich sollte ein Großteil des Depots in solchen Werten liegen, meiner Meinung nach.

Gruss space

[benny_m]

Ich würde eher sagen man befindet sich in USD seit 3 Jahren in einer Seitwärtsbewegung.

Desweiteren hat J&J ja auch einige Probleme und wird deshalb derzeit nicht höher bewertet.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.623.352 von benny_m am 30.11.07 09:03:05

wir befindren uns jetzt am ATH, das schon 2 mal erreicht wurde. kann gut sein, dass es wieder zurück geht, wenn der Widerstand zu groß ist, andersherum ist der weg nach oben frei, wenn er geknackt wird.
Ist heiters Beruferaten. Früher oder später wird er geknackt, weil die Gewinne weiter steigen werden und der Kurs nachfolgen wird.
JNJ ist ein Wachstumsunternehmen, das es von der Bewertung her gar für Value-Leute interessant macht. Solche Situiationen gibts nicht oft!

Gruss space

ier die letzten 5 jahre mit dem Widerstand bei rd. 70 Dollar:



Hier noch news:

Johnson & Johnson to Book $440M Charge
Thursday November 29, 6:06 pm ET
Johnson & Johnson to Book Special $440M Charge Related to Decreased Sales of Heart Drug

NEW YORK (AP) -- Johnson & Johnson expects to record a $440 million one-time charge in the fourth quarter because the company has reduced its future cash flow estimates for NATRECORr, a heart failure drug, according to a regulatory filing Thursday.

ADVERTISEMENT
In the Securities and Exchange Commission filing, the health care products maker said the after-tax, non-cash charge is required to write down the intangible asset related to the treatment.

Despite the recent sales decline that led to the charge, Johnson & Johnson said a subsidiary, Scios Inc., will continue to market NATRECORr.

Johnson & Johnson said the charge will not affect the company's earnings-per-share guidance, which excludes special items.

Johnson & Johnson also reported that it expects to book a special tax gain of about $260 million related to the restructuring of certain international subsidiaries.

The tax gain will also not impact the company's earnings outlook.

Johnson & Johnson shares fell 40 cents to $68 in after-hours trading, after gaining 5 cents to $68.40 during the regular session. Earlier in the day, Johnson & Johnson hit a 52-week high of $68.66.

(This version CORRECTS the amount of the charge.)

[benny_m]

Laut Focus money ein sehr beliebter Wert bei den US-Valueinvestoren. Bin mal gespannt ob es wirklich nach oben geht oder ob es wieder Richtung 60 USD geht.

[spaceistheplace]

HEALTH / VISION CARE

J&J sees potential for contact lens business

PITSINEE JITPLEECHEEP

Johnson & Johnson Vision Care Inc, the optical unit of Johnson & Johnson, has set its sights on expanding its vision-care business in Asia. The maker of Acuvue contact lenses has seen huge growth potential in many emerging markets in Asia, according to Jean Accad, regional vice-president and managing director of Johnson & Johnson Vision Care in Asia Pacific.

He added that Thailand was an important market in Southeast Asia because of the low usage contact lenses relative to its population.

While the penetration rate of contact lenses for vision correction in developed markets such as the United States is as high as 40%, the rates in India and some parts of China are less than 5%.

In Thailand , the rate is estimated at between 10% and 12% in big cities such as Bangkok, while elsewhere in the country it is between 5% and 6%.

Thailand's contact-lens market is estimated to be worth about 1.5 billion baht this year, up 15-20% over last year.

To educate the people about contact lenses, Johnson & Johnson Vision Care set up The Vision Care Institute (TVCI), a non-profit organisation aimed at providing training curricula to ophthalmologists and vision-care practitioners up to the advanced level, said Mr Accad.

The mission of TVCI is to meet the demand of the patients through innovation and education. The institute will also work with the universities and academics in the country where it is located to raise public awareness about the importance of eye care.

Mr Accad said there were now eight TVCI branches worldwide, including one each in Bangkok, Taipei, Seoul, Tokyo and Shanghai. Two more will open in Dubai and Russia next year.

The TVCI in Bangkok, which was opened a year ago, is the centre for Southeast Asia. So far, it has attracted 800 eye-care practitioners, about 600 of whom are from Thailand and the balance from other countries including Malaysia, Singapore, India and the Philippines.

The company expected its TVCI in Bangkok to welcome about 2,000 people next year, about 1,200 of whom will be from Thailand.

[spaceistheplace]

Antwort auf Beitrag Nr.: 32.530.051 von Borger52 am 22.11.07 21:18:22

sorry, aber für solche statements habe ich den Thread nicht geöffnet...